RxDoctor Payments Data

David Jarrett, MD

Psychiatry · Durham, NCNPI 1558438648

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $26,400 of the $27,772 with a category attached, or 95.1%. AbbVie accounts for 96.8% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2019 at $27,634 and has fallen 99.9% since, to $30 in 2022. Among psychiatry clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$27,772in general payments, 2019–2025

Across 63 payments — averaging $440.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$27K
  • Smith+Nephew$318
  • Johnson & Johnson$145
  • Otsuka America Pharmaceutical, Inc.$145
  • Sunovion Pharmaceuticals Inc.$93
  • Neos Therapeutics, LP$50
  • plus $141 from 6 others

What the payments were for

  • Speaking & faculty fees$26,40095%
  • Travel & lodging$2341%
  • Food & beverage$1,1094%
  • Education$300%

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,772 in reported general payments places this provider in the 95th percentile of 1,108 psychiatry providers in North Carolina.

See all psychiatry providers in North Carolina

Medicare billing

Part B allowed, 2024
$59,522
Medicare patients
57
Services billed
715

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl21$36,994
ConcertaMethylphenidate Hcl12$19,155
BelsomraSuvorexant19$8,100
VyvanseLisdexamfetamine Dimesylate12$5,130
Vilazodone Hcl30$4,297
Bupropion XlBupropion Hcl123$3,284
Divalproex Sodium ErDivalproex Sodium31$2,956
Quetiapine Fumarate108$2,746
Memantine Hcl19$2,735
Ziprasidone Hcl17$2,295
Clonazepam174$1,668
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine39$1,647
Doxepin Hcl18$1,427
Escitalopram Oxalate81$1,086
Liothyronine Sodium18$828

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$26,880$36,99421 claims
Johnson & JohnsonConcerta$145$19,15512 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$29$5,13012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,108 psychiatry providers in North Carolina.

Other psychiatry in Durham

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →